191 related articles for article (PubMed ID: 26199649)
1. Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases.
Mi B; Yu C; Pan D; Yang M; Wan W; Niu G; Chen X
Theranostics; 2015; 5(10):1115-21. PubMed ID: 26199649
[TBL] [Abstract][Full Text] [Related]
2. Comparing the Diagnostic Potential of 68Ga-Alfatide II and 18F-FDG in Differentiating Between Non-Small Cell Lung Cancer and Tuberculosis.
Kang F; Wang S; Tian F; Zhao M; Zhang M; Wang Z; Li G; Liu C; Yang W; Li X; Wang J
J Nucl Med; 2016 May; 57(5):672-7. PubMed ID: 26719378
[TBL] [Abstract][Full Text] [Related]
3.
Wu J; Wang S; Zhang X; Teng Z; Wang J; Yung BC; Niu G; Zhu H; Lu G; Chen X
J Nucl Med; 2018 Dec; 59(12):1809-1816. PubMed ID: 29700127
[No Abstract] [Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5.
Wu J; Tian J; Zhang Y; Ji H; Sun J; Wang X; Sun C; Wang L; Teng Z; Lu G; Zhu H; Chen X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2869-2876. PubMed ID: 35138445
[TBL] [Abstract][Full Text] [Related]
6. Combined
Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
[TBL] [Abstract][Full Text] [Related]
7. A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients.
Gao S; Wu H; Li W; Zhao S; Teng X; Lu H; Hu X; Wang S; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2029-37. PubMed ID: 26153145
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between Clinicopathological Characteristics and PET/CT Uptake in Esophageal Squamous Cell Carcinoma: [
Dong Y; Wei Y; Chen G; Huang Y; Song P; Liu S; Zheng J; Cheng M; Yuan S
Mol Imaging Biol; 2019 Feb; 21(1):175-182. PubMed ID: 29869060
[TBL] [Abstract][Full Text] [Related]
9. (18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases.
Yu C; Pan D; Mi B; Xu Y; Lang L; Niu G; Yang M; Wan W; Chen X
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2021-8. PubMed ID: 26121930
[TBL] [Abstract][Full Text] [Related]
10. Complementary roles of tumour specific PET tracer ¹⁸F-FAMT to ¹⁸F-FDG PET/CT for the assessment of bone metastasis.
Morita M; Higuchi T; Achmad A; Tokue A; Arisaka Y; Tsushima Y
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1672-81. PubMed ID: 24006150
[TBL] [Abstract][Full Text] [Related]
11. Improved detection of bone metastases from lung cancer in the thoracic cage using 5- and 1-mm axial images versus a new CT software generating rib unfolding images: comparison with standard ¹⁸F-FDG-PET/CT.
Homann G; Mustafa DF; Ditt H; Spengler W; Kopp HG; Nikolaou K; Horger M
Acad Radiol; 2015 Apr; 22(4):505-12. PubMed ID: 25586709
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases.
Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA
Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313
[TBL] [Abstract][Full Text] [Related]
13. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
[TBL] [Abstract][Full Text] [Related]
14. (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.
Guo J; Guo N; Lang L; Kiesewetter DO; Xie Q; Li Q; Eden HS; Niu G; Chen X
J Nucl Med; 2014 Jan; 55(1):154-60. PubMed ID: 24232871
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of 18F-FDG-negative osteoblastic metastatic bone lesions noted on PET/CT in breast cancer patients.
Al-Muqbel KM; Yaghan RJ; Al-Omari MH; Rousan LA; Dagher NM; Al Bashir S
Nucl Med Commun; 2016 Jun; 37(6):593-601. PubMed ID: 26813990
[TBL] [Abstract][Full Text] [Related]
16. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
[TBL] [Abstract][Full Text] [Related]
17. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
Du Y; Cullum I; Illidge TM; Ell PJ
J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
[TBL] [Abstract][Full Text] [Related]
18. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
Sahin E; Zincirkeser S; Akcan AB; Elboga U
J BUON; 2014; 19(1):291-6. PubMed ID: 24659678
[TBL] [Abstract][Full Text] [Related]
19. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis.
Liu NB; Zhu L; Li MH; Sun XR; Hu M; Huo ZW; Xu WG; Yu JM
Asian Pac J Cancer Prev; 2013; 14(6):3647-52. PubMed ID: 23886160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
